Bittel v. Pfizer, Inc.

307 F. App'x 132
CourtCourt of Appeals for the Tenth Circuit
DecidedJanuary 9, 2009
Docket07-3311
StatusUnpublished
Cited by5 cases

This text of 307 F. App'x 132 (Bittel v. Pfizer, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Tenth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bittel v. Pfizer, Inc., 307 F. App'x 132 (10th Cir. 2009).

Opinion

ORDER AND JUDGMENT *

MICHAEL R. MURPHY, Circuit Judge.

Plaintiff-Appellant Gene Bittel was terminated from his employment with Defendant-Appellee Pfizer, Inc. (“Pfizer”) in June 2005. Bittel alleges he was terminated because of his age in violation of the Age Discrimination in Employment Act (“ADEA”) and various Kansas employment discrimination statutes. Pfizer contends it terminated Bittel because of multiple violations of corporate policy which called his integrity into question and placed Pfizer at risk of violating FDA regulations and Pharmaceutical Research and Manufacturers of America (“PhRMA”) guidelines. While Bittel acknowledges he violated some company policies, he claims the policy violations were pretextual and he was actually terminated because of his age. In support, Bittel argues the following: the company gave varying explanations of his policy vi *134 olations and the reasons for his termination; some of the allegations against him were exaggerated, untrue, or based on nonexistent policies; his younger supervisor’s conduct demonstrated age-based animus towards Bittel; and Pfizer’s regional workforce as a whole was getting younger when he was terminated. The district court granted summary judgment in favor of Pfizer, concluding Bittel had not created a genuine issue of material fact as to pretext. Exercising jurisdiction pursuant to 28 U.S.C. § 1291, we affirm the district court. The evidence, viewed in the light most favorable to Bittel, only casts doubt on some of the purported policy violations cited by Pfizer and does not create a genuine issue of material fact as to pretext.

I. Background 1

Bittel was born in 1955. He became a pharmaceutical sales representative in 2001 with Pharmacia, Inc., and became a Pfizer employee in 2003 when Pfizer acquired Pharmacia. His territory covered the northwestern third of Kansas. For most of Bittel’s tenure at Pfizer, his supervisor was Bill Giltner. Giltner is twelve years younger than Bittel. Bittel was the oldest sales representative on his sales team.

In April 2004, Bittel received a regional sales award. Around the same time, however, Giltner and Giltner’s supervisor, Kevin Malone, placed Bittel on an immediate action plan, a remedial plan to correct perceived deficiencies in Bittel’s selling ability. According to Bittel, Giltner was a demanding and abrasive supervisor. In June 2004, Bittel claims Giltner told him he did not deserve the sales award he had won. Giltner also allegedly told Bittel that Bittel “had no respect for [Giltner] because [Bittel] was so much older than he.” Shortly thereafter, Bittel was placed on a more drastic probationary plan, a performance improvement plan, due to perceived sales deficiencies. Bittel claims these probationary measures were imposed despite his achievement of nearly 100% of his sales goals for the year 2004. At the end of the year, Bittel was taken off formal probationary status, but Giltner indicated Bittel should take part in various organized promotional activities. Giltner also took extensive notes regarding Bit-tel’s job performance and perceived deficiencies, including such things as his dress and language at company meetings. Giltner took more notes on Bittel than he did on any other employee, although he took notes on thirty to forty percent of his employees. Bittel testified Giltner’s managerial style drove another employee to quit. A coworker testified Giltner was demanding of everybody.

Bittel claims he was required to host a teleconference for health care practitioners in early 2005. He made arrangements to co-host a teleconference with another representative, but was told by Giltner he would not be considered the “host.” On short notice, Bittel arranged a separate teleconference, but on the day of the teleconference he learned the facility he had reserved lacked a telephone line. Improvising, he instead passed out printed cop *135 ies of slides which would have been presented had the teleconference taken place and asked the doctors to listen to the teleconference on their own time. Pfizer claims this was a violation of the company’s policies, which closely regulate the form and content of information disseminated to health care practitioners. 2

This violation was reported to Giltner by another sales representative who had been present at the meeting. Without mentioning the violation, Giltner later emailed all of the sales representatives and requested a list of the teleconferences they had hosted so he could award them points as part of a bonus program called ACE. Bittel responded and claimed credit for the botched teleconference. Giltner awarded Bittel the ACE points even though he had already been informed that the teleconference had violated company policy.

Concerned about the teleconference and other perceived violations of company policy, Giltner and Malone arranged a meeting with Bittel. Bittel claims he was not told the purpose of the meeting. Bittel also claims Giltner told him he did not plan on attending the meeting. When Bit-tel arrived, however, Giltner was present. Bittel says this caused him to lose his composure. Bittel was questioned about the teleconference and told several different versions of what went on before telling the truth. During the meeting, Bittel also admitted to copying the teleconference onto a personal CD, which he was told was a violation of Pfizer policy. At the end of the meeting, he claims he was never given a warning or told he was no longer in good standing. After the meeting Malone recommended firing Bittel and drafted a “final warning letter,” but the letter was never sent to Bittel. The following day, Giltner called Bittel on two separate occasions. First, Giltner told Bittel he would not receive a merit pay increase based upon his 2004 sales. Second, Giltner told Bittel his expense report was overdue. Bittel believes the calls were timed to harass him.

Just over a week after the meeting, Bittel organized, with two other sales representatives, a “journal club,” an informal periodic meeting where medical practitioners present recent medical developments to each other. Pharmaceutical representatives sometimes sponsor these gatherings, and Pfizer policy allows for the payment of honoraria to the speakers as long as the audience includes practitioners who are not co-workers of the speaker. Audience members are not entitled to payment. For this event, the sales representatives invited practitioners from multiple clinics, but the only ones who actually attended were co-workers of the speaker. The representatives paid the speaker anyway, and also paid the audience members. Bittel informed Giltner of the event after it had taken place. Giltner reported the incident to Pfizer’s corporate compliance attorneys, but they recommended no discipline of the participating representatives because the policy had evidently generated confusion. The other sales representatives who put on the event were younger than Bittel.

Another Pfizer promotional activity is the awarding of grants for educational events, including continuing medical education seminars. The sales representatives complete grant applications and the applications are submitted to Pfizer for approval.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Forbes v. Kinder Morgan, Inc.
172 F. Supp. 3d 1182 (D. Kansas, 2016)
Monroe v. City of Lawrence
124 F. Supp. 3d 1097 (D. Kansas, 2015)
Roberts v. International Business Machines Corp.
896 F. Supp. 2d 1068 (N.D. Oklahoma, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
307 F. App'x 132, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bittel-v-pfizer-inc-ca10-2009.